Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $8.7 million.

  • Arcutis Biotherapeutics' Cost of Revenue rose 5782.3% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year increase of 12055.43%. This contributed to the annual value of $19.1 million for FY2024, which is 28355.72% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Cost of Revenue stood at $8.7 million for Q3 2025, which was up 5782.3% from $7.5 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Cost of Revenue registered a high of $8.8 million during Q1 2025, and its lowest value of $269000.0 during Q3 2022.
  • Over the past 4 years, Arcutis Biotherapeutics' median Cost of Revenue value was $3.3 million (recorded in 2024), while the average stood at $3.8 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 36556.68% in 2024, then surged by 5782.3% in 2025.
  • Over the past 4 years, Arcutis Biotherapeutics' Cost of Revenue (Quarter) stood at $485000.0 in 2022, then surged by 363.09% to $2.2 million in 2023, then surged by 207.44% to $6.9 million in 2024, then increased by 25.78% to $8.7 million in 2025.
  • Its Cost of Revenue was $8.7 million in Q3 2025, compared to $7.5 million in Q2 2025 and $8.8 million in Q1 2025.